Merck Acquires Cancer Drug Rights

April 17, 2012

April 17, 2012 | Merck has acquired the rights to an Endocyte cancer drug candidate for $120 million and up to $880 million in milestone payments, the companies announced yesterday. Endocyte shares rose 101% after the announcement. Reuters